bullish
Hutchmed China Ltd (13.HK/HCM.US) 23H1 - This Company Is Becoming More Attractive
816 Views07 Aug 2023 08:55
HUTCHMED performed very well in 23H1, making high growth for the full year more certain. Whether fruquintinib gets FDA approval in 23H2 will be a key milestone for the company to stand on a new level.
Boomeranged on Mon, 30 Oct 2023 10:31
We have seen over 35% share price rally after this insight was published. Obviously, the market is optimistic about the upcoming fruquintinib's FDA potential approval in Q4, and has priced in this catalyst. We remain bullish on Hutchmed, because with the potential breakthrough in internationalization and the financial performance of turning losses into profits, qualitative changes are taking place
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
Price Chart(Sign Up to Access)
- China Healthcare Weekly (Sep.1) - China's New IPO Reform, Financing Environment, Junshi Biosciences03 Sep 2023
- What Will BRICS Bring to the World? - The Rise of The Rest30 Aug 2023
- Pre-IPO Sunho Biologics (SHB HK) - High Valuations Can Be Hard to Come By24 Aug 2023
- WuXi AppTec (2359.HK/603259.CH) 23H1 - Is It Time to Start Being Optimistic?03 Aug 2023
- Hutchmed China Ltd (13.HK/HCM.US)- Stronger than Expected and Deserves More Attention from Investors18 May 2023
- Hutchmed China Ltd (13.HK/HCM.US) - The $1.13B Eye-Catching Deal with Takeda and the New Outlook25 Jan 2023
x